Table 2.

Mean arterial pressure for the cardiorespiratory and neuromuscular fitness classifications (mm Hg, mean ± SD)

Classification	Treatment	Group	Time points
			1a	2	3	4	5	6	7
Cardiorespiratory fitness*†	Caffeine	HCF	86.22 ± 9.17	93.67 ± 7.29	108.70 ± 11.04	101.17 ± 3.37	90.53 ± 4.30	104.07 ± 8.43	102.63 ± 8.98
		MCF	92.52 ± 7.30	95.00 ± 7.41	102.00 ± 8.96	98.00 ± 5.58	93.83 ± 6.46	100.00 ± 8.93	105.00 ± 9.66
	Placebo	HCF	85.53 ± 11.61	85.40 ± 5.90	98.07 ± 6.71	89.30 ± 10.79	74.70 ± 27.21	94.23 ± 10.21	98.90 ± 11.06
		MCF	91.28 ± 5.60	91.02 ± 4.29	101.57 ± 4.47	97.40 ± 5.71	82.00 ± 29.04	99.07 ± 6.30	100.37 ± 4.95
Neuromuscular fitness*†	Caffeine	HNF	90.57 ± 9.31	93.27 ± 7.74	104.40 ± 11.05	99.23 ± 5.56	91.27 ± 6.12	101.93 ± 8.96	101.13 ± 8.56
		MNF	88.17 ± 8.34	95.40 ± 6.84	106.30 ± 10.15	99.93 ± 4.11	93.10 ± 5.20	102.13 ± 8.93	106.50 ± 9.36
	Placebo	HNF	87.73 ± 12.20	87.18 ± 5.81	98.80 ± 5.74	90.20 ± 11.60	67.40 ± 36.21	93.07 ± 9.42	96.73 ± 10.15
		MNF	89.08 ± 5.89	89.23 ± 5.89	100.83 ± 6.04	96.50 ± 5.37	89.30 ± 5.95	100.23 ± 6.30	102.53 ± 5.12

^a1 to 7 correspond to time points as follows: 1, 60 min before the start of the trial; 2, immediately before the start of the trial; 3, between the 1st and 2nd periods; 4, immediately after the end of the 2nd period; 5, immediately before the start of the 3rd period; 6: between the 3rd and 4th periods; 7: exhaustion

* Significant main effect of treatment (p < 0.01)

^† Significant main effect of time (p < 0.001)